News Breaks |
|
|
| January 4, 2013 |
| 08:41 EDT |  | FINL, FL, LULU, LLY, AUO, FOLD, SONC, ARAY | On The Fly: Pre-market Movers
HIGHER AFTER GUIDANCE: Eli Lilly (LLY), up 1.7%... ALSO HIGHER: Amicus Theraputics (FOLD), up 8.5% after announcing results from Phase 2 study... AU Optronics (AUO), up 4.7% after DigiTimes said company asked to join Amazon supply chain... LOWER AFTER EARNINGS/GUIDANCE: Finish Line (FINL), down 7%... Sonic (SONC), down 5%... Accuray (ARAY), down 25.5%... ALSO LOWER: Foot Locker (FL), down 2% after disappointing results, guidance of peer Finish Line... lululemon (LULU), down 3.9% after downgrade to Neutral at Credit Suisse. |
|
|
News For FINL;FL;LULU;LLY;AUO;FOLD;SONC;ARAY From The Last 14 Days Check below for free stories on FINL;FL;LULU;LLY;AUO;FOLD;SONC;ARAY the last two weeks. |
|
|
| June 18, 2013 |
| 10:17 EDT |  | LLY | Lilly puts active on FDA says investigating two deaths after Zyprexa injections
 Subscribe for More Information |
|
| 10:12 EDT | | LLY | FDA investigating two deaths of patients taking Lilly's Zyprexa
The FDA said in a safety announcement on its website that it is investigating two unexplained deaths in patients who received an intramuscular injection of the antipsychotic drug Zyprexa. The patients died 3-4 days after receiving an appropriate dose of the drug, well after the 3-hour post-injection monitoring period required under the Zyprexa Risk Evaluation and Mitigation Strategy, the agency said. Both patients were found to have very high olanzapine blood levels after death. Eli Lilly is the maker of Zyprexa. |
|
| June 17, 2013 |
| 11:45 EDT |  | FOLD | Amicus Theraputics price target lowered to $3 from $4 at Leerink
Subscribe for More Information |
|
| 11:34 EDT | | LLY | Eli Lilly: LIVALO 4mg has neutral effects on fasting serum glucose levels
Kowa Pharmaceuticals America and Eli Lilly and Company announced results of a pre-specified safety analysis from the INTREPID (HIV-infected patieNts and TREatment with PItavastatin vs. pravastatin for Dyslipidemia) trial evaluating the effect of LIVALO 4 mg compared with pravastatin 40 mg on changes in levels of blood glucose and glycated hemoglobin in HIV-infected adults with dyslipidemia. INTREPID was a Phase 4, multicenter, 12-week randomized superiority study followed by a 40-week safety extension study comparing the lipid-lowering effects of pitavastatin 4 mg and pravastatin 40 mg in adults with HIV infection and dyslipidemia. The results of this pre-specified safety analysis, presented yesterday at the Endocrine Society's 95th Annual Meeting & Expo in San Francisco, CA, showed neutral effects of pitavastatin 4 mg and pravastatin 40 mg on fasting serum glucose and HbA1c levels over 12 weeks. |
|
| 11:17 EDT |  | LLY | Eli Lilly to host conference call
Subscribe for More Information |
|
| 09:19 EDT | | FOLD | On The Fly: Pre-market Movers
Subscribe for More Information |
|
| 09:04 EDT |  | FOLD | Amicus delays U.S. filing Amigal unit late 2014, TheStreet reports
Subscribe for More Information |
|
| 08:17 EDT | | SONC | Sonic reaches agreement for five new locations in Rochester, NY market
Subscribe for More Information |
|
| 06:09 EDT | | FOLD | Amicus Theraputics to host conference call
Subscribe for More Information |
|
| 06:06 EDT | | LLY | Transition Therapeutics announces exercise of TT-401 rights by Eli Lilly
Transition Therapeutics (TTHI) announced that Eli Lilly (LLY) has exercised its option to assume all development and commercialization rights to type 2 diabetes drug candidate TT-401. In conjunction with this assumption of rights, Transition will receive a $7M milestone payment. Lilly and Transition have amended their agreement to address future development of TT-401 and associated financial arrangements. Lilly will assume all costs and perform all future development and commercialization activities of TT-401. Transition will contribute payment of $14M to Lilly in three separate installments during the Phase 2 clinical study. If TT-401 is successfully commercialized, Transition will be eligible to receive approximately $240M in additional milestone payments. Transition will also be eligible to receive a double-digit royalty on sales of TT-401 products and a low single digit royalty on related compounds. |
| |
| June 14, 2013 |
| 14:38 EDT |  | LULU | Market poised to end week lower amid worries about Fed, Asia
Subscribe for More Information |
|
| June 13, 2013 |
| 16:45 EDT | | LLY | Eli Lilly terminates Phase II study for beta secretase inhibitor
Subscribe for More Information |
|
| 14:36 EDT | | LLY | Lilly, Boehringer Ingelheim support ADA call for review of incretin therapies
Subscribe for More Information |
|
| 14:33 EDT | | LLY | Eli Lilly July volatility elevated into diabetes business update
Subscribe for More Information |
|
| 11:33 EDT | | LULU | lululemon says plans standalone Men's stores by 2016
Subscribe for More Information |
|
| 11:22 EDT | | LULU | lululemon sees international opportunity as large as N.A. opportunity
Subscribe for More Information |
|
| 08:45 EDT | | LULU | lululemonprice target lowered to $52 from $61 at Buckingham
Subscribe for More Information |
|
| 06:05 EDT | | LLY | Eli Lilly, Incyte announce efficacy data of baricitinib Phase 2b JADA study
Subscribe for More Information |
|
| June 12, 2013 |
| 14:22 EDT |  | LULU | lululemon shares continue downtrend following CEO departure news
Subscribe for More Information |
|
| 08:58 EDT | | LULU | lululemon growth strategies remain intact, says Canaccord
After meeting with lululemon's outgoing CEO and members of the board, Canaccord believes that the fundamentals of the company remain sound. The firm does not believe that the CEO stepped down because of the company's quality control issues, and it expects the stock to rebound. The firm reiterates a Buy rating on the shares. |
| |
|
|
|
|
